Novo Nordisk sues Eli Lilly over ads as GLP-1 market hits ‘inflection point’
The Danish company Novo says U.S.-based Lilly isn’t including the most up-to-date clinical information about its drugs.
The Danish company Novo says U.S.-based Lilly isn’t including the most up-to-date clinical information about its drugs. This story matters for Finance & Markets readers tracking option. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. OptionNews curates and briefs the finance & markets stories that matter. Our editorial policy →